Education
About Us
Working with TipRanks
Follow Us
Pure Biologics SA (DE:PQB)
FRANKFURT:PQB
PQB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.42 - €2.79
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.00M
Enterprise ValueN/A
Total Cash (Recent Filing)€227.00K
Total Debt (Recent Filing)€14.42M
Price to Earnings (P/E)―
Beta-0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding8,163,144
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PQB FAQ
What was Pure Biologics SA’s price range in the past 12 months?
Pure Biologics SA lowest stock price was €0.42 and its highest was €2.79 in the past 12 months.
What is Pure Biologics SA’s market cap?
Pure Biologics SA’s market cap is €12.00M.
When is Pure Biologics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pure Biologics SA’s earnings last quarter?
Currently, no data Available
Is Pure Biologics SA overvalued?
According to Wall Street analysts Pure Biologics SA’s price is currently Overvalued.
Does Pure Biologics SA pay dividends?
Pure Biologics SA does not currently pay dividends.
What is Pure Biologics SA’s EPS estimate?
Pure Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Biologics SA have?
Pure Biologics SA has 8,163,144 shares outstanding.
What happened to Pure Biologics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pure Biologics SA?
Currently, no hedge funds are holding shares in DE:PQB
Company Description
Pure Biologics SA
Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.
Technical Analysis
Ryvu Therapeutics SA
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―
Selvita SA
―
Mabion SA
―